Phase II study of iproplatin in advanced ovarian carcinoma

C. Sessa, J. Vermorken, J. Renard, S. Kaye, D. Smith, W. Ten Bokkel Huinink, F. Cavalli, H. Pinedo

Research output: Contribution to journalArticle


Iproplatin (cis-dichloro-trans dihydroxy-bis-isopropylamine platinum [IV]; CHIP) was administered intravenously (IV) at monthly intervals at doses of 300 mg/m2 and 240 mg/m2 to ten previously untreated and 97 previously treated patients with advanced ovarian carcinoma. The overall response rate was 78% among patients with no prior chemotherapy, 42% among patients with prior chemotherapy not including cisplatin, and 22% among patients with prior chemotherapy including cisplatin. Overall response rates to iproplatin were 6.4% and 54% in patients with/without clinical evidence of tumor resistance to cisplatin. Thrombocytopenia was the dose-limiting toxicity, median time to nadir and to recovery being 2 and 4 weeks, respectively. Patients who had received prior chemotherapy regimens for >1 year showed a 10% greater reduction in platelet count (mean platelet nadir ± SD, 57.5 ± 49.96 x 103/μL) and a higher incidence of grade 3 to 4 thrombocytopenia after the first cycle than patients who had received prior chemotherapy regimens for 3/μL). Moderate to severe vomiting and diarrhea occurred in 84% and 16% of patients pretreated with chemotherapy. Neuropathy (6%) was reported only in patients with prior cisplatin treatment. Mild and reversible renal toxicity was observed in 6% of cases. Iproplatin is an active drug in ovarian cancer; the results achieved in patients previously treated with cisplatin strongly suggest that the two drugs are cross-resistant.

Original languageEnglish (US)
Pages (from-to)98-105
Number of pages8
JournalJournal of Clinical Oncology
Issue number1
Publication statusPublished - 1988
Externally publishedYes


ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sessa, C., Vermorken, J., Renard, J., Kaye, S., Smith, D., Ten Bokkel Huinink, W., ... Pinedo, H. (1988). Phase II study of iproplatin in advanced ovarian carcinoma. Journal of Clinical Oncology, 6(1), 98-105.